Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044103485> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2044103485 abstract "In metastatic breast cancer (MBC) patients, randomised controlled trials evaluated Bevacizumab as first-line treatment showed improvements in tumour response rate and progression-free survival (PFS) when added to chemotherapy. In Morocco, we conducted an observational study to investigate clinical features, treatment and prognosis associated with Bevacizumab based chemotherapy in first line treatment of HER2 negative MBC.Nineteen women were included in this study. All these women were diagnosed as having HER2 negative MBC at the National Institute of Oncology in Rabat, Morocco, between January 2009 and December 2010. The median age of patients was 48.1 years. Four patients (21%) had metastatic disease at diagnosis and 15 patients (79%) had received treatment for first metastatic relapse. Bone, liver and lung were the most frequent metastasis sites. Patients were followed up until April 2011. Most patients had objective response; 15.8% of complete response, 47.3% of partial response and 21.1% of stabilisation. Median PFS was estimated at 11.5 months. Sub-groups analysis showed a statistically significant difference (Log-rank test: p = 0.01); PFS for patients receiving Bevacizumab - weekly Paclitaxel was estimated at 18.1 months, and at 9.1 months for patients receiving the combination Bevacizumab - Docetaxel. This benefit in PFS was associated with an acceptable safety profile.As demonstrated in this study, Bevacizumab based chemotherapy in first line treatment of HER2 negative MBC in Morocco and particularly in combination with Taxanes extends PFS, as confirmed in a recent meta-analysis of 3 randomised controlled phase III studies." @default.
- W2044103485 created "2016-06-24" @default.
- W2044103485 creator A5003082935 @default.
- W2044103485 creator A5010882316 @default.
- W2044103485 creator A5041865689 @default.
- W2044103485 date "2012-03-22" @default.
- W2044103485 modified "2023-10-14" @default.
- W2044103485 title "Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study" @default.
- W2044103485 cites W1925212740 @default.
- W2044103485 cites W1985260748 @default.
- W2044103485 cites W2003278673 @default.
- W2044103485 cites W2012469445 @default.
- W2044103485 cites W2019606818 @default.
- W2044103485 cites W2037761545 @default.
- W2044103485 cites W2052066839 @default.
- W2044103485 cites W2054728198 @default.
- W2044103485 cites W2073212944 @default.
- W2044103485 cites W2085992950 @default.
- W2044103485 cites W2091442233 @default.
- W2044103485 cites W2100608628 @default.
- W2044103485 cites W2109134893 @default.
- W2044103485 cites W2124322375 @default.
- W2044103485 cites W2126275851 @default.
- W2044103485 cites W2163003060 @default.
- W2044103485 cites W2166573361 @default.
- W2044103485 cites W2167224460 @default.
- W2044103485 cites W2258266017 @default.
- W2044103485 doi "https://doi.org/10.1186/1756-0500-5-162" @default.
- W2044103485 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3337253" @default.
- W2044103485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22439740" @default.
- W2044103485 hasPublicationYear "2012" @default.
- W2044103485 type Work @default.
- W2044103485 sameAs 2044103485 @default.
- W2044103485 citedByCount "3" @default.
- W2044103485 countsByYear W20441034852013 @default.
- W2044103485 countsByYear W20441034852014 @default.
- W2044103485 countsByYear W20441034852015 @default.
- W2044103485 crossrefType "journal-article" @default.
- W2044103485 hasAuthorship W2044103485A5003082935 @default.
- W2044103485 hasAuthorship W2044103485A5010882316 @default.
- W2044103485 hasAuthorship W2044103485A5041865689 @default.
- W2044103485 hasBestOaLocation W20441034851 @default.
- W2044103485 hasConcept C121608353 @default.
- W2044103485 hasConcept C126322002 @default.
- W2044103485 hasConcept C141071460 @default.
- W2044103485 hasConcept C143998085 @default.
- W2044103485 hasConcept C2775930923 @default.
- W2044103485 hasConcept C2776694085 @default.
- W2044103485 hasConcept C2777802072 @default.
- W2044103485 hasConcept C2779013556 @default.
- W2044103485 hasConcept C2780739268 @default.
- W2044103485 hasConcept C2781190966 @default.
- W2044103485 hasConcept C530470458 @default.
- W2044103485 hasConcept C71924100 @default.
- W2044103485 hasConceptScore W2044103485C121608353 @default.
- W2044103485 hasConceptScore W2044103485C126322002 @default.
- W2044103485 hasConceptScore W2044103485C141071460 @default.
- W2044103485 hasConceptScore W2044103485C143998085 @default.
- W2044103485 hasConceptScore W2044103485C2775930923 @default.
- W2044103485 hasConceptScore W2044103485C2776694085 @default.
- W2044103485 hasConceptScore W2044103485C2777802072 @default.
- W2044103485 hasConceptScore W2044103485C2779013556 @default.
- W2044103485 hasConceptScore W2044103485C2780739268 @default.
- W2044103485 hasConceptScore W2044103485C2781190966 @default.
- W2044103485 hasConceptScore W2044103485C530470458 @default.
- W2044103485 hasConceptScore W2044103485C71924100 @default.
- W2044103485 hasIssue "1" @default.
- W2044103485 hasLocation W20441034851 @default.
- W2044103485 hasLocation W20441034852 @default.
- W2044103485 hasLocation W20441034853 @default.
- W2044103485 hasLocation W20441034854 @default.
- W2044103485 hasOpenAccess W2044103485 @default.
- W2044103485 hasPrimaryLocation W20441034851 @default.
- W2044103485 hasRelatedWork W144521535 @default.
- W2044103485 hasRelatedWork W1967868926 @default.
- W2044103485 hasRelatedWork W1999702412 @default.
- W2044103485 hasRelatedWork W2119832281 @default.
- W2044103485 hasRelatedWork W2328551487 @default.
- W2044103485 hasRelatedWork W2411890706 @default.
- W2044103485 hasRelatedWork W2468666928 @default.
- W2044103485 hasRelatedWork W2525832560 @default.
- W2044103485 hasRelatedWork W3200352014 @default.
- W2044103485 hasRelatedWork W4248552131 @default.
- W2044103485 hasVolume "5" @default.
- W2044103485 isParatext "false" @default.
- W2044103485 isRetracted "false" @default.
- W2044103485 magId "2044103485" @default.
- W2044103485 workType "article" @default.